Rosiglitazone inhibits IL-8 and MCP-1 production via a PPARγ-dependent mechanism in LPS-stimulated HK-2 cells.

Abstract

<p>(A, B) HK-2 cells were pretreated with rosiglitazone (5, 10, 20 µM) in the absence or presence of GW9662 (10, 30, 100 µM) for 2 hours and then treated with 1 μg/ml LPS for 4 hours. IL-8 and MCP-1 mRNA was analyzed by real-time PCR. (C, D) HK-2 cell were pretreated with 10 µM rosiglitazone in the absence or presence of 100 µM GW9662 for 2 hours and then treated with 1 μg/ml LPS for 24 hours. IL-8 and MCP-1 protein in cell supernatants was measured by ELISA. Results are shown as mean ± SD and representative of three independent experiments. *<i>P</i><0.05 compared to the control group; ^<i>#</i><i>P</i><0.05 compared to the LPS-treated group; ^<i>&</i><i>P</i><0.05 compared to LPS + RGL (10 µM)-treated group. </p